Genmab — April 2026
-
√
-
Novo Nordisk får fine bløderdata med i New England Journal of Medicine
Blødermidlet mim8, der er sendt til godkendelse i USA, er udviklet i samarbejde med Genmab.
(medwatch.dk)
-
here is the abstract for that article SugarAlf referred to - The New England Journal of Medicine - Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors - https://www.nejm.org/doi/full/10.1056/NEJMoa2517384
-
and a press release - Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM https://www.prnewswire.com/news-releases/denecimig-mim8-significantly-reduced-annualized-bleeding-rate-in-people-with-hemophilia-a-regardless-of-inhibitor-status-in-phase-3-data-published-in-nejm-302757974.html
-
AbbVie Pipeline Update
April 2026
(for Epkinly ) https://investors.abbvie.com/static-files/5bb173b5-053e-4e6e-b028-c82cf2ee96a0 -
Jan van de Winkel, Ph.D.
Taking the stage as a keynote speaker at the Antibody & ADC Summit in Shanghai https://www.linkedin.com/posts/janvandewinkel_biotech-innovationinscience-patientimpact-activity-7455280931638132736-2yD1
-
time frame
for outcome measures all reduced to 1.5yrs for RAINFOL-02 https://clinicaltrials.gov/study/NCT06619236?tab=history&a=18&b=19&compareMode=sideBySide#version-content-panel
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind